tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
Company AnnouncementsBioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
6d ago
BioInvent’s BI-1808 Shows Promise in Early Phase 2a CTCL Trial
PremiumCompany Announcements
BioInvent’s BI-1808 Shows Promise in Early Phase 2a CTCL Trial
7d ago
BioInvent Publishes Promising Early Data for BI-1607 in Cancer Treatment
PremiumCompany Announcements
BioInvent Publishes Promising Early Data for BI-1607 in Cancer Treatment
26d ago
BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation
PremiumCompany Announcements
BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation
27d ago
BioInvent’s BI-1910 Shows Promise in Phase 1 Trials for Solid Tumors
PremiumCompany Announcements
BioInvent’s BI-1910 Shows Promise in Phase 1 Trials for Solid Tumors
1M ago
BioInvent to Present Promising Phase 2a Data at ASH 2025
PremiumCompany AnnouncementsBioInvent to Present Promising Phase 2a Data at ASH 2025
1M ago
BioInvent to Present Promising BI-1808 Data at ASH 2025
Premium
Company Announcements
BioInvent to Present Promising BI-1808 Data at ASH 2025
1M ago
BioInvent’s Earnings Call: Strategic Gains Amid Financial Challenges
Premium
Company Announcements
BioInvent’s Earnings Call: Strategic Gains Amid Financial Challenges
1M ago
BioInvent’s Strategic Focus on Lead Cancer Therapies
PremiumCompany Announcements
BioInvent’s Strategic Focus on Lead Cancer Therapies
2M ago
BioInvent Prioritizes Advanced Programs to Boost Cancer Therapy Development
PremiumCompany Announcements
BioInvent Prioritizes Advanced Programs to Boost Cancer Therapy Development
2M ago
BioInvent to Present Interim Report for January-September 2025
PremiumCompany Announcements
BioInvent to Present Interim Report for January-September 2025
2M ago
BioInvent and Transgene’s BT-001 Shows Promising Results in Cancer Treatment
PremiumCompany Announcements
BioInvent and Transgene’s BT-001 Shows Promising Results in Cancer Treatment
2M ago
BioInvent and Transgene Reveal Promising BT-001 Clinical Data at ESMO 2025
PremiumCompany AnnouncementsBioInvent and Transgene Reveal Promising BT-001 Clinical Data at ESMO 2025
2M ago
BioInvent Launches Phase 2a Trial for BI-1206 in NSCLC and Uveal Melanoma
Premium
Company Announcements
BioInvent Launches Phase 2a Trial for BI-1206 in NSCLC and Uveal Melanoma
2M ago
BioInvent to Present Phase 1 Data for BI-1910 at SITC
Premium
Company Announcements
BioInvent to Present Phase 1 Data for BI-1910 at SITC
2M ago
BioInvent Announces Board of Directors Update
PremiumCompany Announcements
BioInvent Announces Board of Directors Update
3M ago
BioInvent Reports Strong Q2 2025 Earnings and Clinical Progress
PremiumCompany Announcements
BioInvent Reports Strong Q2 2025 Earnings and Clinical Progress
4M ago
BioInvent Restructures Portfolio to Focus on Lead Cancer Immunotherapy Programs
PremiumCompany Announcements
BioInvent Restructures Portfolio to Focus on Lead Cancer Immunotherapy Programs
4M ago
BioInvent Sharpens Focus on Advanced Clinical Assets for Growth
PremiumCompany Announcements
BioInvent Sharpens Focus on Advanced Clinical Assets for Growth
4M ago
BioInvent and Transgene to Present Promising BT-001 Study Results at ESMO 2025
PremiumCompany AnnouncementsBioInvent and Transgene to Present Promising BT-001 Study Results at ESMO 2025
5M ago
BioInvent’s BI-1808 Shows Promising Results in Phase 2a CTCL Study
Premium
Company Announcements
BioInvent’s BI-1808 Shows Promising Results in Phase 2a CTCL Study
6M ago
BioInvent Reports Positive Phase 1 Results for Cancer Therapy
Premium
Company Announcements
BioInvent Reports Positive Phase 1 Results for Cancer Therapy
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >